Gloucester Pharmaceuticals

Biopharmaceutical company that developed ISTODAX (romidepsin), an HDAC inhibitor for T-cell lymphoma. Acquired by Celgene in 2009.

Location
Cambridge, Massachusetts, USA
Founded
2003
Investors
1
Categories
biotech, oncology, epigenetics, acquired

Investors

NameLocationTypeStagesPortfolio
Apple Tree PartnersNew York, USAbiotech-focused
series-aseries-b+2
23